India’s private hospital sector shows contrasting strategies as Apollo Hospitals reports faster revenue growth with broad diversification, while Max Healthcare emphasises hospital efficiency and capacity expansion, highlighting differing paths to growth in the booming market.
India’s private hospital industry has been one of the steadier growth stories in the market, helped by higher insurance cover, a willingness to pay for better treatment and a persistent shortage of beds in major cities. Against that backdrop, Apollo Hospitals and Max Healthcare remain two of the sector’s most closely watched names, with both having recently reported June quarter results that highlight different ways of playing the same opportunity.
Apollo Hospitals delivered faster top-line growth in the quarter ended June 2026, with consolidated revenue rising 21% year on year to ₹7,043 crore, according to reports from Mint and Kotak Neo. Net profit climbed 34% to about ₹581 crore, while EBITDA increased 28% to ₹1,092 crore, leaving the group with a margin of 15.5%. The numbers underline Apollo’s scale and the benefit of its broader business mix, which goes well beyond hospitals into pharmacies, diagnostics and digital health.
Max Healthcare, by contrast, remains a more concentrated hospital operator, and its latest results reflected that focus. Reports from Sahi and Kotak Neo show network revenue rose roughly 16% to between ₹2,366 crore and ₹2,982 crore, depending on the measure used, with EBITDA at ₹598 crore to ₹704 crore and profit after tax up about 5%. The company’s operating margin of 24.8% remains among the strongest in the industry, although higher depreciation, finance costs and integration expenses limited bottom-line growth.
That margin gap is central to the comparison. Apollo’s hospital business is efficient, but its consolidated profitability is diluted by lower-margin retail and digital operations. Max, meanwhile, has a cleaner hospital-led model and is running existing beds more intensively, with occupancy around 75% versus Apollo’s roughly 70% in the quarter. Apollo still has the larger footprint, with 77 hospitals and nearly 9,857 beds, compared with Max’s 21 facilities and just over 6,100 beds, and its balance sheet is lighter, with net debt of about ₹748 crore against Max’s roughly ₹2,384 crore as of 30 June 2026.
Both groups are expanding aggressively. Apollo has outlined plans to add about 5,800 beds over the coming years at a cost of roughly ₹11,150 crore, while Max is aiming to more than double capacity to around 14,500 beds through a mix of owned, brownfield and asset-light expansion. Max’s market value of around ₹1.1 lakh crore shows how highly investors already prize its operating efficiency and growth runway. Apollo, on the other hand, offers greater scale, broader diversification and faster revenue growth. Which stock looks better positioned ultimately depends on whether investors prefer focused profitability or a larger, more varied healthcare platform.
Disclaimer: This article is intended to inform and educate, not to recommend or endorse any financial product, investment or strategy. Please consider your own financial circumstances and seek professional advice where appropriate before making financial decisions.
